Drug-coated Balloon Catheter Market

The global drug-coated balloon catheter market accounted for USD 0.699 billion in 2023 and is estimated to reach USD 1.64 billion by 2034 with a CAGR of 8.06% during the forecast period 2024-2034. The rising prevalence of cardiovascular diseases, the growing preference for minimally invasive procedures, advances in interventional cardiology, government initiatives, and reimbursement policies, and the growing elderly population will drive market expansion.

Cardiovascular disorders (CVDs), including coronary artery disease (CAD) and peripheral artery disease (PAD), are serious public health concerns around the world. The increased frequency of these illnesses, which are frequently related to lifestyle factors such as smoking, an unhealthy diet, and sedentary behavior, increases the demand for effective treatment options such as drug-coated balloon catheters. For instance, Medtronic announced in January 2022 that the drug-coated balloon IN.PACTTM AdmiralTM would be launched in Japan to treat peripheral artery disease.

By type, the paclitaxel segment accounted for the highest revenue-grossing segment in the global drug-coated balloon catheter market in 2023 owing to the proven efficacy in reducing restenosis rates and improving patient outcomes in peripheral artery disease (PAD) treatment. For instance, the FDA approved Abbott's Pantheris SV (Small Vessel) image-guided atherectomy system in February 2022 for the management of peripheral artery disease. Additionally, the Sirolimus segment is predicted to grow at the fastest CAGR during the forecast period owing to the superior antiproliferative properties, favorable safety profile, and increasing adoption in coronary artery disease (CAD) interventions.

By product, the peripheral vascular disease segment accounted for the highest revenue-grossing segment in the global drug-coated balloon catheter market in 2023 owing to the rising prevalence of peripheral artery disease (PAD) globally and the effectiveness of drug-coated balloon catheters in treating this condition. For instance, Philips announced the release of the most recent iteration of the Azurion image-guided therapy platform in March 2022, which offers improved workflow capabilities for interventional operations. Additionally, the coronary artery disease segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing incidences of coronary artery disease globally and the continuous development of innovative drug-coated balloon catheters tailored for coronary interventions.

By end-user, the hospital segment accounted for the highest revenue-grossing segment in the global drug-coated balloon catheter market in 2023 owing to the high volume of procedures performed in hospital settings, availability of specialized medical staff, and advanced infrastructure for interventional cardiology procedures. For instance, Cardinal Health reported in March 2022 that the transfer of its Cordis business to Hellman & Friedman for an estimated $1 billion had been completed. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for outpatient procedures, cost-effectiveness, and technological advancements allowing for more complex interventions in ambulatory settings.

North American region is anticipated to have the highest revenue share during the forecast period owing to advanced healthcare infrastructure, high prevalence of cardiovascular diseases, favorable reimbursement policies, and extensive research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to rapid urbanization, increasing healthcare expenditure, rising prevalence of cardiovascular diseases, and growing adoption of advanced medical technologies across emerging economies. For instance, Concept Medical Inc.'s ground-breaking MagicTouch Sirolimus Coated Balloon (SCB) was granted an Investigational Device Exemption (IDE) by the US Food & Drug Administration in April 2023 for the purpose of treating small vessels (SV) in coronary arteries.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Type, Product, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: Drug-coated Balloon Catheter Market Report 2023 - 2034

Drug-coated Balloon Catheter Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)

• Paclitaxel
• Sirolimus

Drug-coated Balloon Catheter Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

• Coronary Artery Disease
• Peripheral Vascular Disease

Drug-coated Balloon Catheter Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospital
• Clinics
• Ambulatory Surgical Centers

Drug-coated Balloon Catheter Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA